Chemo Iberica S.A.

Publication No. WO/2009/087151 Published on July 16, Assigned to Chemo Iberica for Polymorphic Hydrate Crystalline Form (Italian Inventors)
US Fed News Service, Including US State News; 7/17/2009; 397 words; ...have developed polymorphic hydrate crystalline forms of Moxifloxacin hydrochloride. The patent has been assigned to Chemo Iberica S.A., Barcelona, Spain. According to an abstract posted by the World Intellectual Property Organization, in the...

Chemo Iberica considers US acquisition.
Pharma Marketletter; 2/25/2008; 371 words; Spain's Chemo Iberica, which is engaged in the development of drug raw materials, the production of generics and, more recently, R&D for...

PHARMACEUTICAL ACQUISITION.(Ivax Corp. acquires ChemSource Corp.)(Brief Article)
Caribbean Update; 3/1/2003; 598 words; ...acquired ChemSource Corporation in Puerto Rico from Chemo Iberica, S.A. and Quimica Sintetica S.A. ChemSource develops, manufactures and sells...facility complement those now manufactured at Ivax's facility in the Czech Republic, said Phillip Frost...

Caution -- skulduggery afoot
Pharmaceutical Executive; 4/1/1999; 1793 words; ...identifies Flack and Whybrow's contact at Bayer as Stephen...Holliday Chemicals, Uquifa's parent, in Huddersfield...a London law firm that a Chemo-Iberica lawyer had visited. The...International, one of the world's leading firms of private...